Cadrenal Therapeutics, Inc. (CVKD) Misses Q2 EPS by 61c

Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported Q2 EPS of ($1.87), $0.61 worse than the analyst estimate of ($1.26). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Cadrenal Therapeutics, Inc. (CVKD) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• MARA amends Texas power site purchase agreement, posts $100M deposit
• Bimegren Energy (BESS) files $100M mixed shelf